Skip to main content
OpenTrials
Completed

NCT Number: NCT00284973

A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and immunogenicity of 3 doses and 2 vaccination schedules.

This blood stage candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prophylaxis Against Plasmodium Falciparum Malaria Infections Malaria Mosquito-Borne Diseases Parasitic Diseases Protozoan Infections Vector Borne Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Shanghai Changhai Hospital

Shanghai, China

About this study

This is a double blind, randomized, controlled Phase I study of PfCp2.9, an experimental malaria vaccine candidate, adjuvanted with Montanide ISA 720.

The primary objective of this study is to assess the safety and reactogenicity of the vaccine in healthy Chinese adult volunteers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female ≥ 18 and ≤ 45 years of age
  • Agrees not to donate blood during the course of the trial.
  • Signed written informed consent provided.
  • Available to participate for the study duration.

Exclusion criteria

  • History of allergic reactions following any vaccination.
  • Involvement in drug or other vaccine trial within four weeks prior to the trial.
  • Acute illness within four weeks prior to the trial.
  • Presence of fever at the time of vaccination, i.e. body temperature (by axillary) > 37.5 C.
  • Presence of any chronic illness/disease including diabetes mellitus, tuberculosis, leprosy, epilepsy and hypertension determined by medical history or examination.
  • Persons on systemic corticosteroids, immunomodulators or anticoagulants within four weeks prior to vaccination.
  • Persons with a history of allergic manifestations requiring treatment with injectable antihistamines, adrenaline or steroids.
  • Pregnancy. Women should not be pregnant, lactating, or planning pregnancy throughout the study period. A urinary pregnancy test (immuno-chromatography) will be performed for all women of child-bearing potential at entry and prior to each vaccination. Adequate contraception throughout the study should be used if applicable.
  • Sexually active woman not using contraceptives.
  • Current smoker ( ≥ 20 cigarettes/day).
  • History of malaria: persons with a known history of malaria or with positive markers for antibodies to malaria parasite by IFA and/or ELISA.
  • History of residing in a malaria endemic region or malaria exposure (travel) within last two years.
  • Abnormal hematology and clinical chemistry considered to be clinically significant.
  • Abnormal urine routine test considered to be clinically significant
  • Persons with positive markers for HBV (HBsAg) and/or HCV (Anti-HCV) infection.

Treatment and study plan

Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720

Biological

Primary outcomes

  1. To assess the safety and reactogenicity of the PfCP-2.9 /Montanide ISA 720 vaccine in healthy adult volunteers.

Secondary outcomes

  1. To assess the immunogenicity of the PfCP-2.9/Montanide ISA 720 vaccine in healthy adult volunteers by evaluating and comparing antigen-specific antibody responses (anti-PfCP-2.9 ELISA) after each vaccination.

  2. For exploratory analysis:

  3. To assess in vitro inhibition of parasite growth by vaccine-induced antibodies as measured by the GIA

  4. To assess the relationship between antibody levels as measured by ELISA with the corresponding degree of in vitro parasite growth inhibition as measured by GIA

  5. To assess antigen-specific antibody responses by IFA after each vaccination

  6. To assess the relationship between antibody levels as measured by ELISA with IFA titers that recognize the conformational antigens of the parasite.

Sponsors and collaborators

Lead sponsor

Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.

Industry

Collaborators

  • PATH
  • Second Military Medical University
  • World Health Organization
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Registry information

Official study title

Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers

Important dates

Study start
2006
First posted
Feb 1, 2006
Registry last updated
Apr 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.